Inmune Bio (INMB) EBT Margin (2021 - 2025)
Inmune Bio (INMB) posted EBT Margin of 38554.0% for Q1 2025, up 84.5% sequentially from 248785.71% in Q1 2024, and up 21023171.0% YoY from N/an in Q1 2024.
Inmune Bio (INMB) EBT Margin (2021 - 2025) Analysis & Trends
Inmune Bio has reported EBT Margin for 5 years, with the latest figure at 38554.0% in Q1 2025.
- Quarterly EBT Margin rose 21023171.0% year-over-year to 38554.0% in Q1 2025, while the trailing twelve-month figure through Dec 2025 was 117308.0% (up 147649200.0% YoY) and the FY2025 annual result came in at 164186.0%, up 32383543.0% from the prior year.
- EBT Margin improved to 38554.0% in Q1 2025 per INMB's latest filing, from 248785.71% in the prior quarter.
- Over five years, EBT Margin peaked at 4241.1% in Q1 2022 and troughed at 637325.0% in Q1 2021.
- A 5-year average of 154827.09% and a median of 33082.14% in 2023 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2022 and 2024: EBT Margin surged 63308390 bps in 2022, then plunged 23027256 bps in 2024.
- Over 5 years, EBT Margin stood at 5809.2% in 2021, then dropped by 15 bps to 6700.0% in 2022, then plunged by 394 bps to 33082.14% in 2023, then sank by 652 bps to 248785.71% in 2024, then jumped by 85 bps to 38554.0% in 2025.
- According to Business Quant data, EBT Margin over the past three periods registered 38554.0%, 248785.71%, and 33082.14% for Q1 2025, Q1 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 13.77% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -25.06% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -2.67% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 12.09% |
| 10 | Inmune Bio | 61.59 Mn | 43.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -38,554.00% |
| Mar 31, 2024 | -248,785.71% |
| Dec 31, 2023 | -33,082.14% |
| Sep 30, 2023 | -31,206.98% |
| Jun 30, 2023 | -15,308.70% |
| Mar 31, 2023 | -18,513.16% |
| Dec 31, 2022 | -6,700.00% |
| Sep 30, 2022 | -543,309.18% |
| Jun 30, 2022 | -42,831.25% |
| Mar 31, 2022 | -4,241.10% |
| Dec 31, 2021 | -5,809.20% |
| Sep 30, 2021 | -387,085.71% |
| Mar 31, 2021 | -637,325.00% |